OR WAIT null SECS
Susan Haigney is lead editor of BioPharm International®.
September 23, 2024
Approvals were recommended for treatments of ovarian cancer, lung cancer, bleeding disorders, respiratory disease, and more.
New and existing technologies, as well as a patient-centric focus, are pushing drug formulation into exciting directions.
September 17, 2024
Novo Nordisk will use Korro Bio’s OPERA platform to develop RNA editing candidates for two targets to treat cardiometabolic diseases.
September 11, 2024
During a presentation at the PDA/FDA Joint Regulatory Conference, Nicholas Violand of Johnson & Johnson and Paul Palmer of Paul R. Palmer Limited discussed how aging facilities can impact the quality of pharmaceutical products.
September 10, 2024
Susan J. Schniepp, member of the editorial advisory boards for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International, provides an update on her experience working in the pharmaceutical industry and what she sees for the industry’s future.
September 09, 2024
CDER’s Jonathan Chapman, senior policy advisor, and Takeda’s Paulien Groll, head of Compliance Excellence, discussed how companies can be proactive with their CAPA strategies instead of reactive, at the 2024 PDA/FDA Joint Regulatory Conference.